A feature on renewed interest in an area where the difficulty for drugmakers is matched only by the potential rewards.
The last two decades have been fraught with advances and setbacks in the neuroscience space as the pharma industry targets one of the most challenging organs of the body—the brain. Since 2000, several pharma companies including Glaxo SmithKline (LSE: GSK) and Pfizer (NYSE: PFE), have reduced their investment in the central nervous…
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
• All the news that moves the needle in pharma and biotech. • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. • Receive The Pharma Letter daily news bulletin, free forever.
• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription.
CNS DiseasesCompanies, mergers and acquisitionsDealsFeatureIn DepthLicensingNeurologicalPharmaceutical
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.
The Pharma Letter 39 to 43 Putney High Street Putney London SW15 1SP
For trial and subscription enquiries please email [email protected]
For editorial enquiries, press releases and events please email [email protected]
For all other queries please email [email protected]
Agile web development by Byte9